Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LEAD Therapeutics Inc.

Division of BioMarin Pharmaceutical Inc.
www.leadtherapeutics.com

Latest From LEAD Therapeutics Inc.

Licensing PARP Inhibitor A Win For BioMarin, Medivation

BioMarin’s licensing of the PARP inhibitor talazoparib to Medivation in August reduces BioMarin’s development expenses and helps it to meet its stated goal of being non-GAAP earnings positive in 2017. Medivation gets another compound it can develop in key oncology indications it is already pursuing with its core product, the prostate cancer drug Xtandi.

BioPharmaceutical Deals

BeiGene CEO John Oyler On Investing In Biotech In China: An Interview With PharmAsia News (Part 2 of 2)

BeiGene CEO John Oyler discusses what is missing in China’s venture capital environment if it truly wants to foster innovation. Based in Beijing, BeiGene’s lead product entered the clinic in 2013.

BioPharmaceutical China

BeiGene CEO John Oyler On Investing In Biotech In China: An Interview With PharmAsia News (Part 1 Of 2)

BeiGene CEO John Oyler discusses what is missing in China’s venture capital environment if it truly wants to foster innovation. Based in Beijing, BeiGene’s lead product entered the clinic in 2013.

BioPharmaceutical China

WuXi Venture Fund Managing Director Sofie Qiao On Taking Risks: An Interview With PharmAsia News

WuXi AppTec Inc. has largely invested along with established venture funds since its launch in 2011 backed by $50 million of investor funds. But the humble student aims to evolve and invest more boldly, says newly appointed managing director Sofie Qiao.

BioPharmaceutical China
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • BioMarin Pharmaceutical Inc.
  • Senior Management
  • Peter Myers , PhD, CEO
    Leonard Post, PhD, CSO
  • Contact Info
  • LEAD Therapeutics Inc.
    Phone: (650) 737-1630
    999 Bayhill Dr.
    Ste. 130
    San Bruno, CA 94066
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register